Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Titel:
Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Auteur:
Daveson, A. James M. Ee, Hooi C. Andrews, Jane M. King, Timothy Goldstein, Kaela E. Dzuris, John L. MacDougall, James A. Williams, Leslie J. Treohan, Anita Cooreman, Michael P. Anderson, Robert P.